The Department of Veterans Affairs has decided not to cover a new Alzheimer’s drug from Biogen (BIIB), citing insufficient evidence of “a robust and meaningful clinical benefit” and concerns about safety, according to a notice issued by the agency.
However, the VA said it will make exceptions for “highly selected patients” and listed several hurdles that must be cleared before the medicine will be covered, such as requiring it to be prescribed by providers who specialize in treating dementia and ensuring patients had recently received MRI brain scans.
Create a display name to comment
This name will appear with your comment
